<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684138</url>
  </required_header>
  <id_info>
    <org_study_id>C-06-40</org_study_id>
    <nct_id>NCT00684138</nct_id>
  </id_info>
  <brief_title>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)</brief_title>
  <official_title>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, parallel group, subject masked, multi-center six (6) month follow-up study
      comparing ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 implanted in both eyes
      to ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL Model SN6AD3 implanted in both eyes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular Distance Corrected Near Visual Acuity at Best Distance (That Which Provides the Subject With the Best Vision)</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular Distance Corrected Near Visual Acuity at Best Distance (that which provides the subject with the best vision)measured in mean logMAR. logMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA). Mean logMAR is the average value of visual acuity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binocular Distance Corrected Distance Visual Acuity</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Binocular Distance Corrected Distance Visual Acuity measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 50 cm)</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 50 cm) measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 60 cm)</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 60 cm)measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 70 cm)</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 70 cm) measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>ReSTOR Aspheric +3.0D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReSTOR Aspheric +4.0D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</intervention_name>
    <description>Intraocular Lens</description>
    <arm_group_label>ReSTOR Aspheric +4.0D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</intervention_name>
    <description>Intraocular Lens</description>
    <arm_group_label>ReSTOR Aspheric +3.0D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Adults, 21 years of age or older at the time of surgery, of either gender or any race,
             diagnosed with bilateral cataracts

          -  Calculated lens power is within the available range

          -  Willing and able to complete all required postoperative visits

          -  Planned cataract removal by phacoemulsification and/or liquifacture

          -  Potential postoperative visual acuity of 0.2 logMAR or better in study eyes

          -  Preoperative astigmatism of 1.0 Diopter (D) or less, measured by keratometry in study
             eyes

          -  Clear intraocular media other than cataract in study eyes

          -  Able to comprehend and sign a statement of informed consent

          -  Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR, or
             if BCDVA is equal to or better than 0.2 logMAR, BCDVA with a Brightness Acuity Tester
             (BAT) on &quot;Medium&quot; setting must be worse than 0.2 logMAR

        Exclusion:

          -  Significant irregular corneal aberration as demonstrated by corneal topography

          -  Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or
             other retinal disorders) that are predicted to cause future acuity losses to a level
             worse than 0.2 logMAR

          -  Subjects who may reasonably be expected to require laser treatments at any time

          -  Previous corneal refractive surgery

          -  Amblyopia

          -  Clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial
             dystrophy)

          -  Diabetic retinopathy

          -  Extremely shallow anterior chamber, not due to swollen cataract

          -  Microphthalmos

          -  Previous retinal detachment

          -  Previous corneal transplant

          -  Recurrent severe anterior or posterior segment inflammation of unknown etiology

          -  Rubella or traumatic cataract

          -  Iris neovascularization

          -  Glaucoma (uncontrolled or controlled with medication)

          -  Aniridia

          -  Optic nerve atrophy

          -  Pregnancy

          -  Current or previous usage of an alpha-1-selective adrenoceptor blocking agent or an
             antagonist of alpha 1A adrenoceptor (e.g.Flomax® (tamsulosin HCL), Hytrin®, or
             Cardura®)

          -  Any subject currently participating in another investigational drug or device study
             that may confound the results of this investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Call Center for Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <results_first_submitted>January 30, 2009</results_first_submitted>
  <results_first_submitted_qc>February 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2010</results_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Tonya Tubbs Jones</name_title>
    <organization>Alcon</organization>
  </responsible_party>
  <keyword>cataract</keyword>
  <keyword>cataract surgery</keyword>
  <keyword>IOL</keyword>
  <keyword>intraocular lens</keyword>
  <keyword>ReSTOR</keyword>
  <keyword>Replacement of cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only adult subjects of either gender or any race in need of cataract extraction in both eyes were considered for enrollment. 280 subjects were implanted bilaterally with either the ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 or the ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL Model SN6AD3 based upon a 1:1 randomization.</recruitment_details>
      <pre_assignment_details>Subjects were examined to ensure inclusion/exclusion criteria. Only subjects who signed an informed consent and qualified to be in the study were enrolled. Subject numbers were assigned after obtaining consent meeting inclusion/exclusion criteria. Subjects were considered enrolled once implanted in the first operative eye.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACRYSOF® ReSTOR® +3.0</title>
          <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
        </group>
        <group group_id="P2">
          <title>ACRYSOF® ReSTOR® Aspheric +4.0</title>
          <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACRYSOF® ReSTOR® +3.0</title>
          <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
        </group>
        <group group_id="B2">
          <title>ACRYSOF® ReSTOR® Aspheric +4.0</title>
          <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Binocular Distance Corrected Near Visual Acuity at Best Distance (That Which Provides the Subject With the Best Vision)</title>
        <description>Binocular Distance Corrected Near Visual Acuity at Best Distance (that which provides the subject with the best vision)measured in mean logMAR. logMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA). Mean logMAR is the average value of visual acuity.</description>
        <time_frame>3 months</time_frame>
        <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>ACRYSOF® ReSTOR® +3.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
          </group>
          <group group_id="O2">
            <title>ACRYSOF® ReSTOR® Aspheric +4.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular Distance Corrected Near Visual Acuity at Best Distance (That Which Provides the Subject With the Best Vision)</title>
          <description>Binocular Distance Corrected Near Visual Acuity at Best Distance (that which provides the subject with the best vision)measured in mean logMAR. logMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA). Mean logMAR is the average value of visual acuity.</description>
          <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.0539" upper_limit="0.0854"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.0854" upper_limit="0.1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Binocular Distance Corrected Distance Visual Acuity</title>
        <description>Binocular Distance Corrected Distance Visual Acuity measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
        <time_frame>3 months post-operative</time_frame>
        <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>ACRYSOF® ReSTOR® +3.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
          </group>
          <group group_id="O2">
            <title>ACRYSOF® ReSTOR® Aspheric +4.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular Distance Corrected Distance Visual Acuity</title>
          <description>Binocular Distance Corrected Distance Visual Acuity measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
          <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.065" upper_limit="-0.040"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.061" upper_limit="-0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 50 cm)</title>
        <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 50 cm) measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
        <time_frame>3 months post-operative</time_frame>
        <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>ACRYSOF® ReSTOR® +3.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
          </group>
          <group group_id="O2">
            <title>ACRYSOF® ReSTOR® Aspheric +4.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 50 cm)</title>
          <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 50 cm) measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
          <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.0384" upper_limit="0.0849"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.2188" upper_limit="0.2667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 60 cm)</title>
        <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 60 cm)measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
        <time_frame>3 months post-operative</time_frame>
        <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>ACRYSOF® ReSTOR® +3.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
          </group>
          <group group_id="O2">
            <title>ACRYSOF® ReSTOR® Aspheric +4.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 60 cm)</title>
          <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 60 cm)measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
          <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.0916" upper_limit="0.1381"/>
                    <measurement group_id="O2" value="0.32" lower_limit="0.2972" upper_limit="0.3451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 70 cm)</title>
        <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 70 cm) measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
        <time_frame>3 months post-operative</time_frame>
        <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>ACRYSOF® ReSTOR® +3.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens</description>
          </group>
          <group group_id="O2">
            <title>ACRYSOF® ReSTOR® Aspheric +4.0</title>
            <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular Distance Corrected Intermediate Visual Acuity (Tested at 70 cm)</title>
          <description>Binocular Distance Corrected Intermediate Visual Acuity (tested at 70 cm) measured in logMAR. LogMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA).</description>
          <population>Only patients bilaterally implanted with the test article were considered for the outcome measures. One study lens was removed following implantation, but prior to surgery completion, resulting in 279 subjects who were implanted and available for postoperative follow-up (evaluable for All Implanted Analysis).</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.1597" upper_limit="0.2062"/>
                    <measurement group_id="O2" value="0.34" lower_limit="0.3190" upper_limit="0.3669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to six months after cataract surgery.</time_frame>
      <desc>Adverse events were collected from the time of cataract surgery until pre-market approval submission for all 300 patients enrolled in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>ACRYSOF® ReSTOR® +3.0 (First Eyes)</title>
          <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens - First eye implanted only</description>
        </group>
        <group group_id="E2">
          <title>ACRYSOF® ReSTOR® Aspheric +4.0 (First Eyes)</title>
          <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens - First eye implanted only</description>
        </group>
        <group group_id="E3">
          <title>ACRYSOF® ReSTOR® +3.0 (Second Eyes)</title>
          <description>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens - Second eye implanted only</description>
        </group>
        <group group_id="E4">
          <title>ACRYSOF® ReSTOR® Aspheric +4.0 (Second Eyes)</title>
          <description>ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens - Second eye implanted only</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hypopyon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Macular Edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Lens Dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical reintervention (SI)</sub_title>
                <description>Some eyes experienced SI and more than 1 SAE. SN5AD1 (1st Eye): 1 patient - hypopyon, endophthalmitis; 1 patient - lens dislocation; and 1 patient - after the close of the study. SN6AD3 (1st Eye): 1 patient - later had macular edema.</description>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Data from one investigator, who implanted 20 subjects, were excluded from analysis due to non compliance with data collection and documentation. This resulted in 280 implanted subjects that were considered evaluable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

